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1. Problem: Global obesity epidemics
2. Unmet need: Safe and effective anti-obesity drug
3. Solution: leptiPOL™ - intranasal conjugated leptin 
formulation
4. Capital & time 
requirement $15M (up to 20X ROI, 7-10 years)
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innovation value - rightleft - innovation competence
patient
segments
We are a pharmaceutical company focused on development of leptin based anti-
obesity intranasal formulation

























































































































Obesity is not a personal 
choice, its a disease.
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•	Estimated annual obesity 
market size $1.7B. 
•	US population: 313M
•	EU popolation: 711M
IV. Current Treatment Options & Limitations
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1. Diet & Exercise Low compliance 
2. Supplements Unknown	efficacy	
3. OTD & Rx Drugs Unwanted side effects
4. Surgery High risks & costs
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V. Obesity Market Unmet Needs
-9oneuro TM 6
1.	Immediate	efficacy
2. Safety of chronic use
3. Ease of administration
4. Low side effects
5. Independence of diet and exercise
6. Wideness of safe dose range
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VI. Leptin Role in Obesity 
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Leptin is a hormone produced in adipose tissue. It lowers appetite and signals the 
body to burn fat.
In obese patients, 
receptor mediated 
leptin transport 
to the brain is 
impaired (leptin 
desensitization).
In healthy persons, 
leptin transported to 
the brain throught 
BBB, via leptin 
receptors
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•	Independence of diet and 
exercise
•	Convenience of intranasal 
delivery
•	Safety	(overdose,	fluctuation)
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IX. Preclinical Data
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Treatment with leptiPOL reduces food intake and body 
weight
LeptiPOL crosses blood brain barrier and reaches 
brain independent of leptin transporter
Intranasal administration is convenient and effective 
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X. Intellectual Property Porfolio 
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Extensive IP portfolio (over 30 patent and patent applications) 
exclusively licensed to NeuroNano Pharma
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X. Intellectual Property  Positioning 
-9oneuro TM 12
IP positions secured in United States and 
number	of	strategically	identified	countries:	
Europe, Japan, Australia, Canada, & Russia
Opinions on Freedom to Operate are in process
Branding strategy and implementation efforts 
has been initiated
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XI. Commercialization Pathway 
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Phase B Phase C
up to $6M
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XII. Why Invest in NeuroNano Pharma?  
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1. Problem: Global obesity epidemics
2. Need: Delivery of leptin to the brain 
3. Solution:
leptiPOL™ HM - intranasal conjugated leptin 
formulation
4. Secured IP:
Over 30 patents and patent applications covering 
defined	regional	markets
5. Up to 20X ROI:
With $15M capital requirement up to 20X ROI in 
7-10 years
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XII. Thank you!
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Questions?
Please contact Z...
Zagit Gaymalov, Ph.D. 
zgaymalov@neuro10-9.com
+1.402.957.4290
www.neuro10-9.com
